Cargando…
Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects
BACKGROUND: High mobility group box-1 (HMGB-1) is a nuclear protein also acting as inflammatory mediator, whilst osteoprotegerin (OPG), member of tumor necrosis factor receptor superfamily, is indicated as marker of vascular calcification. Peripheral artery disease (PAD) and type 2 diabetes (T2D) ar...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549317/ https://www.ncbi.nlm.nih.gov/pubmed/28789654 http://dx.doi.org/10.1186/s12933-017-0581-z |
_version_ | 1783255952277897216 |
---|---|
author | Giovannini, Silvia Tinelli, Giovanni Biscetti, Federico Straface, Giuseppe Angelini, Flavia Pitocco, Dario Mucci, Luciana Landolfi, Raffaele Flex, Andrea |
author_facet | Giovannini, Silvia Tinelli, Giovanni Biscetti, Federico Straface, Giuseppe Angelini, Flavia Pitocco, Dario Mucci, Luciana Landolfi, Raffaele Flex, Andrea |
author_sort | Giovannini, Silvia |
collection | PubMed |
description | BACKGROUND: High mobility group box-1 (HMGB-1) is a nuclear protein also acting as inflammatory mediator, whilst osteoprotegerin (OPG), member of tumor necrosis factor receptor superfamily, is indicated as marker of vascular calcification. Peripheral artery disease (PAD) and type 2 diabetes (T2D) are clinical conditions characterized by elevated serum inflammatory markers and vascular calcification enhancement. The aim of this study was to investigate the potential role of HMGB-1, OPG and several inflammatory mediators such as C-reactive protein (HsCRP), tumor necrosis factor-alpha and interleukin-6 (IL-6) on the presence and severity of peripheral artery disease in patients with T2D. METHODS: In this retrospective observational study, we have analyzed HMGB-1, OPG and inflammatory cytokines serum levels in 1393 type 2 diabetic patients with PAD and without PAD (WPAD). RESULTS: HMGB-1 (7.89 ± 15.23 ng/mL), OPG (6.54 ± 7.76 pmol/L), HsCRP (15.6 ± 14.4 mg/L) and IL-6 (56.1 ± 28.6 pg/mL) serum levels were significantly higher in patients with PAD than in those WPAD (3.02 ± 8.12 ng/mL, P ˂ 0.001; 2.98 ± 2.01 pmol/L, P < 0.001; 7.05 ± 4.4 mg/L, P < 0.001; 37.5 ± 20.2 pg/mL, P < 0.001 respectively). Moreover HMGB-1 (P < 0.001), OPG (P < 0.001), HsCRP (P < 0.001) and IL-6 (P < 0.001) serum levels were positively correlated with clinical severity of PAD. HMGB-1 (adjusted OR 12.32; 95% CI 3.56–23.54, P = 0.023) and OPG (adjusted OR 3.53; 95% CI 1.54–6.15, P = 0.019) resulted independent determinants of PAD in patients with T2D after adjusting for the conventional cardiovascular risk factor and established inflammatory mediators. CONCLUSIONS: In T2D patients HMGB-1 and OPG serum levels are higher in patients affected by PAD and independently associated with its occurrence and clinical severity. |
format | Online Article Text |
id | pubmed-5549317 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55493172017-08-11 Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects Giovannini, Silvia Tinelli, Giovanni Biscetti, Federico Straface, Giuseppe Angelini, Flavia Pitocco, Dario Mucci, Luciana Landolfi, Raffaele Flex, Andrea Cardiovasc Diabetol Original Investigation BACKGROUND: High mobility group box-1 (HMGB-1) is a nuclear protein also acting as inflammatory mediator, whilst osteoprotegerin (OPG), member of tumor necrosis factor receptor superfamily, is indicated as marker of vascular calcification. Peripheral artery disease (PAD) and type 2 diabetes (T2D) are clinical conditions characterized by elevated serum inflammatory markers and vascular calcification enhancement. The aim of this study was to investigate the potential role of HMGB-1, OPG and several inflammatory mediators such as C-reactive protein (HsCRP), tumor necrosis factor-alpha and interleukin-6 (IL-6) on the presence and severity of peripheral artery disease in patients with T2D. METHODS: In this retrospective observational study, we have analyzed HMGB-1, OPG and inflammatory cytokines serum levels in 1393 type 2 diabetic patients with PAD and without PAD (WPAD). RESULTS: HMGB-1 (7.89 ± 15.23 ng/mL), OPG (6.54 ± 7.76 pmol/L), HsCRP (15.6 ± 14.4 mg/L) and IL-6 (56.1 ± 28.6 pg/mL) serum levels were significantly higher in patients with PAD than in those WPAD (3.02 ± 8.12 ng/mL, P ˂ 0.001; 2.98 ± 2.01 pmol/L, P < 0.001; 7.05 ± 4.4 mg/L, P < 0.001; 37.5 ± 20.2 pg/mL, P < 0.001 respectively). Moreover HMGB-1 (P < 0.001), OPG (P < 0.001), HsCRP (P < 0.001) and IL-6 (P < 0.001) serum levels were positively correlated with clinical severity of PAD. HMGB-1 (adjusted OR 12.32; 95% CI 3.56–23.54, P = 0.023) and OPG (adjusted OR 3.53; 95% CI 1.54–6.15, P = 0.019) resulted independent determinants of PAD in patients with T2D after adjusting for the conventional cardiovascular risk factor and established inflammatory mediators. CONCLUSIONS: In T2D patients HMGB-1 and OPG serum levels are higher in patients affected by PAD and independently associated with its occurrence and clinical severity. BioMed Central 2017-08-08 /pmc/articles/PMC5549317/ /pubmed/28789654 http://dx.doi.org/10.1186/s12933-017-0581-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Original Investigation Giovannini, Silvia Tinelli, Giovanni Biscetti, Federico Straface, Giuseppe Angelini, Flavia Pitocco, Dario Mucci, Luciana Landolfi, Raffaele Flex, Andrea Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects |
title | Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects |
title_full | Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects |
title_fullStr | Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects |
title_full_unstemmed | Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects |
title_short | Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects |
title_sort | serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549317/ https://www.ncbi.nlm.nih.gov/pubmed/28789654 http://dx.doi.org/10.1186/s12933-017-0581-z |
work_keys_str_mv | AT giovanninisilvia serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects AT tinelligiovanni serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects AT biscettifederico serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects AT strafacegiuseppe serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects AT angeliniflavia serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects AT pitoccodario serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects AT mucciluciana serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects AT landolfiraffaele serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects AT flexandrea serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects |